Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate alzheimer disease

Archives of Neurology

Volumn 69, Issue 8, 2012, Pages 1002-1010

  Blennow, Kaj ^a   Zetterberg, Henrik ^a   Rinne, Juha O ^b   Salloway, Stephen ^c   Wei, Jenny ^d   Black, Ronald ^f   Grundman, Michael ^e   Liu, Enchi ^d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c BROWN UNIVERSITY   (United States)

^d Janssen Alzheimer Immunotherapy   (United States)

^e Global R and D Partners   (United States)

^f PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[X 40]; AMYLOID BETA PROTEIN[X 42]; BAPINEUZUMAB; BIOLOGICAL MARKER; PLACEBO; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFECT; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; NERVE CELL DEGENERATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; TREND STUDY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; COHORT STUDIES; DOUBLE-BLIND METHOD; ENGLAND; FEMALE; FINLAND; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; TAU PROTEINS; TREATMENT OUTCOME; UNITED STATES;

EID: 84863750982     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2012.90     Document Type: Article

References (30)

1. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003;2(10):605-613. (Pubitemid 37162569)
2. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368(9533):387-403. (Pubitemid 44108123)
3. Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010;9(7):560-574.
4. Schroeter S, Khan K, Barbour R, et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci. 2008;28(27):6787-6793.
5. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6(8):916-919. (Pubitemid 30644751)
6. Buttini M, Masliah E, Barbour R, et al. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci. 2005;25(40):9096-9101. (Pubitemid 41500817)
7. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837-842.
8. Gilman S, Koller M, Black RS, et al; AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64(9):1553-1562. (Pubitemid 40617691)
9. Salloway S, Sperling R, Gilman S, et al; Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab inmild to moderate Alzheimer disease. Neurology. 2009;73(24):2061-2070.
10. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363-372.
11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944. (Pubitemid 14076461)
12. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol . 1980;7(5):486-488. (Pubitemid 10073130)
13. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
14. Blennow K, Zetterberg H, Minthon L, et al. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett. 2007;419(1):18-22. (Pubitemid 46694097)
15. Hesse C, Rosengren L, Vanmechelen E, et al. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis. 2000;2(3-4):199-206. (Pubitemid 32095607)
16. Blennow K, Wallin A, Ågren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995;26(3):231-245. (Pubitemid 26002016)
17. Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000;285(1):49-52. (Pubitemid 30224621)
18. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56(6):673-680. (Pubitemid 29266465)
19. Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367-385.
20. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131-144.
21. Blennow K. Biomarkers in Alzheimer's disease drug development. Nat Med. 2010;16(11):1218-1222.
22. Blennow K, Fredman P, Wallin A, et al. Protein analysis in cerebrospinal fluid, II: reference values derived from healthy individuals 18-88 years of age. Eur Neurol. 1993;33(2):129-133. (Pubitemid 23100537)
23. Buerger K, Ewers M, Pirttilä T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006;129(Pt 11):3035-3041. (Pubitemid 44684523)
24. Hampel H, Bürger K, Pruessner JC, et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol. 2005;62(5):770-773.
25. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43(3):321-332. (Pubitemid 39061125)
26. Serrano-Pozo A, William CM, Ferrer I, et al. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain. 2010;133(pt 5):1312-1327.
27. Öst M, Nylén K, Csajbok L, et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology. 2006;67(9):1600-1604.
28. Sämgård K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E. Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. Int J Geriatr Psychiatry. 2010;25(4):403-410.
29. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology. 2010;74(19):1531-1537.
30. Portelius E, Bogdanovic N, Gustavsson MK, et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol. 2010;120(2):185-193.